Litcius/Paper detail

KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate

Agnès B. Jousset, Saoussen Oueslati, Cécile Emeraud, Rémy A. Bonnin, Laurent Dortet, Bogdan I. Iorga, Thierry Naas

2021Antimicrobial Agents and Chemotherapy31 citationsDOIOpen Access PDF

Abstract

Resistance to the ceftazidime (CAZ)-avibactam (AVI) combination is increasingly being reported. Here, we report a CAZ-AVI-resistant Klebsiella pneumoniae strain belonging to the high-risk sequence type 307 (ST307) clone and producing Klebsiella pneumoniae carbapenemase 39 (KPC-39), a single-amino-acid variant of KPC-3 (A172T). Cloning experiments, steady-state kinetic parameters, and molecular dynamics simulations revealed a loss of carbapenemase activity and increased affinity for CAZ. KPC-39 was identified in a patient without prior exposure to CAZ-AVI, suggesting silent dissemination in European health care settings.

Topics & Concepts

Klebsiella pneumoniaeMicrobiologyclone (Java method)CeftazidimeBiologyKlebsiella infectionsEnterobacteriaceaeKlebsiellaCloning (programming)VirologyDrug resistanceBacteriaEscherichia coliStrain (injury)Antibiotic resistanceMolecular cloningPlasmidBacterial proteinGenotypeBeta-lactamSequence (biology)Antibacterial agentCross infectionAntibiotic Resistance in BacteriaMicrobial Natural Products and BiosynthesisBacterial Identification and Susceptibility Testing